Agios To Present at September Investor Conferences
Agios Pharmaceuticals (NASDAQ: AGIO) announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Agios Pharmaceuticals (NASDAQ: AGIO) announced its participation in two upcoming investor conferences. The Citi’s 16th Annual Biopharma Virtual Conference will feature a panel on Sickle Cell and related conditions on September 10 at 12:30 p.m. ET. Additionally, the 2021 Cantor Virtual Global Healthcare Conference is scheduled for September 27 at 8:00 a.m. ET. Live webcasts will be available on their website, with replays accessible for at least two weeks post-event. Agios focuses on innovative treatments for genetically defined diseases, with its leading drug candidate, mitapivat, targeting hemolytic anemias.
Details
News Market Reaction – AGIO
The recorded move for AGIO in the trading session of this news was -2.35%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism developing and delivering innovative treatments for genetically defined diseases, today announced that the company is scheduled to present at the following September investor conferences:
- Citi’s 16th Annual Biopharma Virtual Conference
Panel: Sickle Cell, Beta-Thal, ITP & PKD - Measuring Industry Progress in Benign Hematology
Friday, September 10 at 12:30 p.m. ET
- 2021 Cantor Virtual Global Healthcare Conference
Monday, September 27 at 8:00 a.m. ET
Live webcasts of the presentations can be accessed under “Events & Presentations” in the Investors section of the company's website at www.agios.com. Replays of the webcasts will be archived on the Agios website for at least two weeks following each presentation.
About Agios
Agios is focused on discovering and developing novel investigational medicines to treat genetically defined diseases through scientific leadership in the field of cellular metabolism. The company’s most advanced drug candidate is a first-in-class pyruvate kinase R (PKR) activator, mitapivat, that is currently being evaluated for the treatment of three distinct hemolytic anemias. In addition to its active late-stage clinical pipeline, Agios has multiple novel, investigational therapies in clinical and preclinical development. For more information, please visit the company’s website at www.agios.com.
Contacts
Investors:
1AB
Steve Klass
steve@1abmedia.com
Media:
Jessi Rennekamp, 857-209-3286
Director, Corporate Communications
Jessica.Rennekamp@agios.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.